TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12791621

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 1 mg nicotine and 0 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 0 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 1 mg nicotine and 50 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 50 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 1 mg nicotine and 100 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg nicotine and 100 mg caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 mg nicotine and 0 mg caffeine)
Number of subjects: 12
Study: 10669280

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane 5%
Number of subjects: 80
Study: 8839527

Group type: EXPERIMENTAL
Intervention: Tympanic membrane temperature measurement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 37
Study: 1338387

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 60 mg daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 16
Study: 31953727

Group type: EXPERIMENTAL
Intervention: Polypectomy with careful inspection during both insertion and withdrawal
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Standard colonoscopy (polypectomy during withdrawal only)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Control group (standard colonoscopy)
Number of subjects: 1142
Study: 29323617

Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with oncology care
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 350
Study: 27552934

Group type: EXPERIMENTAL
Intervention: Approval by the Medical Ethics Review Committee (METC)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Number of documents required for approval
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Costs charged for approval procedures
Number of subjects: 2
Study: 24148020

Group type: EXPERIMENTAL
Intervention: Immediate loading of implants with a converted pre-existing denture on the day of surgery.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed loading of implants (control group) with soft-relined pre-existing denture.
Number of subjects: 42
Study: 22475087

Group type: EXPERIMENTAL
Intervention: Group hypnosis
Number of subjects: 220

Group type: COMPARATOR
Intervention: Group relaxation
Number of subjects: 220
Study: 20159816

Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1 (527 patients)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Cisplatin/infusional fluorouracil (526 patients)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Cisplatin/infusional fluorouracil
Number of subjects: 1053
Study: 17621644

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily (titrated to a maximum of 120 mg daily)
Number of subjects: 177
Study: 16449090

Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methadone and LAAM
Number of subjects: 40
Study: 12560163

Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix25
Number of subjects: 151

Group type: COMPARATOR
Intervention: Human insulin 30/70
Number of subjects: 151
Study: 10767227

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation program including 3 months of breathing retraining and chest physiotherapy, 3 months of daily supervised exercise, and 6 months of weekly supervised breathing exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 9549298

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8350293

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3747613

Group type: EXPERIMENTAL
Intervention: Immediate lymphadenectomy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Delayed lymphadenectomy
Number of subjects: 171

Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 171
Study: 30071894

Group type: COMPARATOR
Intervention: Exclusion diets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bimuno® galactooligosaccharide (B‐GOS®) prebiotic intervention
Number of subjects: 30
Study: 26885681

Group type: EXPERIMENTAL
Intervention: TACE with ginsenoside Rg3
Number of subjects: 228

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 228
Study: 24751462

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 21751299

Group type: EXPERIMENTAL
Intervention: Intensive treatment acceptance
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: RCT participation
Number of subjects: 106
Study: 20938953

Group type: EXPERIMENTAL
Intervention: Intraoral removal of proximal submandibular stones (IORS group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Submandibular gland resection (SMGR group)
Number of subjects: 44
Study: 19189603

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 1.25‐8.75 mg per day
Number of subjects: 25
Study: 16291415

Group type: EXPERIMENTAL
Intervention: Topiramate (25-600 mg/d for 26 weeks)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 12558761

Group type: EXPERIMENTAL
Intervention: Queckenstedt's maneuver in the supine position
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Queckenstedt's maneuver in the sitting position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of pain increase between supine and upright positions
Number of subjects: 25
Study: 10511769

Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 341
Study: 7572704

Group type: EXPERIMENTAL
Intervention: 30 g ethanol
Number of subjects: 37

Group type: COMPARATOR
Intervention: equienergetic fruit juice
Number of subjects: 37
Study: 1938771

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (Alupent) metered dose inhaler
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 7006708

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation with cyclophosphamide (CY) 60 mg/kg/day for 2 days, 1000 rad total body irradiation, and a marrow transplant from a genotypically identical normal twin.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Immunotherapy consisting of killed autologous leukemic cells and/or normal twin peripheral blood lymphocytes.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified, but includes patients who did not receive additional chemotherapy before CY).
Number of subjects: 34
Study: 30802897

Group type: EXPERIMENTAL
Intervention: Engagement interview
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control visit
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120
Study: 28287818

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over 3 months)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 184
Study: 25802961

Group type: EXPERIMENTAL
Intervention: Low-intensity wheelchair training (30%–40% heart rate reserve, twice a week, 30 mins per session for 16 weeks)
Number of subjects: 29
Study: 23490326

Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 188

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate
Number of subjects: 188
Study: 21434339

Group type: EXPERIMENTAL
Intervention: Tongnao Huoluo Acupuncture (THA) in Group A
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: THA in Group D
Number of subjects: 397

Group type: COMPARATOR
Intervention: Thrombolysis with urokinase in Group B
Number of subjects: 397

Group type: COMPARATOR
Intervention: Batroxobin in Group C
Number of subjects: 397

Group type: COMPARATOR
Intervention: Body acupuncture in Group E
Number of subjects: 397

Group type: COMPARATOR
Intervention: Conventional treatment in Group F
Number of subjects: 397
Study: 19174427

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic strategies
Number of subjects: 0
Study: 17244100

Group type: EXPERIMENTAL
Intervention: Individualized education and coaching session (20 minutes)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standardized information on controlling pain (Control group)
Number of subjects: 67
Study: 14623806

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis (within 2 hours)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Primary PCI (within 2 hours)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis (>=2 hours)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Primary PCI (>=2 hours)
Number of subjects: 834
Study: 10808980

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention course
Number of subjects: 338

Group type: COMPARATOR
Intervention: Knowledge-oriented general health course
Number of subjects: 338
Study: 8828938

Group type: EXPERIMENTAL
Intervention: iodoxamide tromethamine (LT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine (KT)
Number of subjects: 40
Study: 1643920

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Clinical data, lung function, chest roentgenogram, and serologic parameters
Number of subjects: 58
Study: 3887394

Group type: EXPERIMENTAL
Intervention: Prophylactic anti-lymphocyte globulin (ALG) combined with azathioprine and steroids for 8.7 +/- 2.25 days after transplantation, followed by cyclosporine and steroids.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine and steroids only (control group).
Number of subjects: 0
Study: 29338113

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg (97/103 mg)
Number of subjects: 376

Group type: COMPARATOR
Intervention: olmesartan 20 mg
Number of subjects: 376
Study: 27097799

Group type: EXPERIMENTAL
Intervention: PA-intervention (n=29)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Baseline OPA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Baseline LTPA
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: OPA directly recorded
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LTPA directly recorded
Number of subjects: 67
Study: 24341948

Group type: EXPERIMENTAL
Intervention: 750 mg metronidazole tablet (Flagyl®)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 3 g of 15% metronidazole benzoate gel
Number of subjects: 13
Study: 22172481

Group type: EXPERIMENTAL
Intervention: Home training with inexpensive, self‐contained trainer boxes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulation center training using standard video trainers
Number of subjects: 20
Study: 19913119

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (single infusion)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (sodium chloride infusion)
Number of subjects: 46
Study: 17656480

Group type: EXPERIMENTAL
Intervention: D2 + PAN dissection
Number of subjects: 260

Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 260
Study: 16257245

Group type: EXPERIMENTAL
Intervention: Bach flower remedies
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12677972

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 60
Study: 10492054

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 40 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 169

Group type: COMPARATOR
Intervention: Controlled-release morphine 45 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Controlled-release morphine 90 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 169
Study: 8564100

Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 micrograms in 4 ml saline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2119575

Group type: EXPERIMENTAL
Intervention: Dipyridamole (treated for two days prior to surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (direct addition to vein segments in vitro)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (in the absence of arachidonic acid)
Number of subjects: 0
Study: 6988176

Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone in an oily cream base
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone 17-butyrate cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oily cream base alone
Number of subjects: 60
Study: 31829186

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (educational meeting, implementation team, workshops)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single implementation strategy (educational meeting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single implementation strategy
Number of subjects: 0
Study: 28732523

Group type: EXPERIMENTAL
Intervention: Collabri model for collaborative care (CC)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard detection
Number of subjects: 480

Group type: COMPARATOR
Intervention: Case finding (with the recommended screening tool Major Depression Inventory (MDI))
Number of subjects: 480
Study: 26010755

Group type: EXPERIMENTAL
Intervention: Osteoporosis Choice decision aid
Number of subjects: 79

Group type: COMPARATOR
Intervention: FRAX only and Usual Care
Number of subjects: 79
Study: 24321466

Group type: EXPERIMENTAL
Intervention: Emergency/physical exam-indicated cerclage in twin pregnancies
Number of subjects: 43

Group type: COMPARATOR
Intervention: Emergency/physical exam-indicated cerclage in singleton pregnancies
Number of subjects: 43
Study: 22914509

Group type: EXPERIMENTAL
Intervention: Increased authenticity of instructional formats (paper, DVD, standardized patient)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper case
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More authentic instructional formats
Number of subjects: 0
Study: 19230029

Group type: EXPERIMENTAL
Intervention: Intravenous glutathione 1,400 mg administered three times a week for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo administered three times a week for 4 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous glutathione 1,400 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17302768

Group type: EXPERIMENTAL
Intervention: Decision support (DS) intervention with computerized physician order entry (CPOE) for transfusion orders
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Conventional education intervention
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Control group (no DS intervention)
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: DS-recommended orders
Number of subjects: 1752
Study: 15358690

Group type: EXPERIMENTAL
Intervention: bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 11334206

Group type: EXPERIMENTAL
Intervention: Leukodepletion and aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9739333

Group type: EXPERIMENTAL
Intervention: 3 MU IFN alpha 2a for 48 weeks (group I, n = 37)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 9 MU IFN alpha 2a for 48 weeks (group II, n = 39)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 9 MU IFN alpha 2a for 48 weeks (group III, n = 45)
Number of subjects: 76
Study: 7525192

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic with potassium-sparing diuretic, β-blocker, or ACE inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker with β-blocker or ACE inhibitor
Number of subjects: 0
Study: 2532136

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 627044

Group type: EXPERIMENTAL
Intervention: 50 mg tartrazine
Number of subjects: 122
Study: 30896192

Group type: EXPERIMENTAL
Intervention: Digital gambling accelerator intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Brief motivational interviewing (MI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 87
Study: 28178298

Group type: EXPERIMENTAL
Intervention: Albendazole (400mg)
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Praziquantel (40mg/kg)
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Strongyloidiasis (observational analysis)
Number of subjects: 2705
Study: 25007736

Group type: EXPERIMENTAL
Intervention: Navigation system
Number of subjects: 32

Group type: COMPARATOR
Intervention: No navigation system
Number of subjects: 32
Study: 23728830

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 132
Study: 21197536

Group type: EXPERIMENTAL
Intervention: Levosimendan in addition to conventional heart failure therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional heart failure therapy (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levosimendan in addition to conventional therapy
Number of subjects: 24
Study: 19491859

Group type: EXPERIMENTAL
Intervention: Balsalazide 3.3 g (1.1 g tablet, twice daily for 8 weeks)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (twice daily for 8 weeks)
Number of subjects: 249
Study: 18020939

Group type: EXPERIMENTAL
Intervention: Acculturation
Number of subjects: 526

Group type: COMPARATOR
Intervention: Perceived neighborhood safety/aesthetics
Number of subjects: 526
Study: 16157113

Group type: EXPERIMENTAL
Intervention: High-dose vaginal misoprostol (600 microg x 1, then 400 microg every 4 hours x 5)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol (oxytocin 277-1667 mU/min plus 400 microg x 1, then 200 microg every 6 hours x 2, then 100 microg x 1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-dose vaginal misoprostol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol
Number of subjects: 38
Study: 12496952

Group type: EXPERIMENTAL
Intervention: Amino-acid drink containing tryptophan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Amino-acid drink without tryptophan (Control)
Number of subjects: 18
Study: 10071506

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with osteopenia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with osteoporosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with normal density
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (osteoarthritis patients)
Number of subjects: 72
Study: 7729398

Group type: EXPERIMENTAL
Intervention: Protective mask
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Protective jacket
Number of subjects: 160

Group type: COMPARATOR
Intervention: No RPDs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Successful evacuation with RPDs
Number of subjects: 160
Study: 2118322

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg daily, orally
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cephalexin 250 mg four times a day, orally
Number of subjects: 86
Study: 6112447

Group type: EXPERIMENTAL
Intervention: UK‐37 248 (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 30115415

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing education
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group with reminder report
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357
Study: 27630092

Group type: EXPERIMENTAL
Intervention: Four implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Six implants
Number of subjects: 50
Study: 24793076

Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation (grade V)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation positioning (no thrust)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Grade IV patellar mobilisation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Grade I patellar mobilisation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study: 23078148

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (100/10 μg b.i.d.)
Number of subjects: 0
Study: 20381580

Group type: EXPERIMENTAL
Intervention: Provoked without reward for aggression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provoked with reward for aggression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not provoked with reward for aggression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not provoked without reward for aggression
Number of subjects: 0
Study: 18537467

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) at acupuncture point Large Intestine 4 (Hegu)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo acupuncture (PA) at a sham point
Number of subjects: 20
Study: 16174840

Group type: EXPERIMENTAL
Intervention: Number Needed to Treat (NNT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative measures of benefits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absolute measures of therapeutic yield
Number of subjects: 0